Frontiers in Immunology (Mar 2023)

Vitamin B12 attenuates leukocyte inflammatory signature in COVID-19 via methyl-dependent changes in epigenetic markings

  • Larissa M. G. Cassiano,
  • Larissa M. G. Cassiano,
  • Vanessa Cavalcante-Silva,
  • Marina S. Oliveira,
  • Bárbara V. O. Prado,
  • Cristianne G. Cardoso,
  • Anna C. M. Salim,
  • Gloria R. Franco,
  • Vânia D’Almeida,
  • Saionara C. Francisco,
  • Roney S. Coimbra

DOI
https://doi.org/10.3389/fimmu.2023.1048790
Journal volume & issue
Vol. 14

Abstract

Read online

COVID-19 induces chromatin remodeling in host immune cells, and it had previously been shown that vitamin B12 downregulates some inflammatory genes via methyl-dependent epigenetic mechanisms. In this work, whole blood cultures from moderate or severe COVID-19 patients were used to assess the potential of B12 as adjuvant drug. The vitamin normalized the expression of a panel of inflammatory genes still dysregulated in the leukocytes despite glucocorticoid therapy during hospitalization. B12 also increased the flux of the sulfur amino acid pathway, that regulates the bioavailability of methyl. Accordingly, B12-induced downregulation of CCL3 strongly and negatively correlated with the hypermethylation of CpGs in its regulatory regions. Transcriptome analysis revealed that B12 attenuates the effects of COVID-19 on most inflammation-related pathways affected by the disease. As far as we are aware, this is the first study to demonstrate that pharmacological modulation of epigenetic markings in leukocytes favorably regulates central components of COVID-19 physiopathology.

Keywords